


**Product Name** : Z-360  
**Cat. No.** : PC-45389  
**CAS No.** : 209219-38-5  
**Molecular Formula** : C<sub>29</sub>H<sub>36</sub>N<sub>4</sub>O<sub>5</sub>  
**Molecular Weight** : 520.6199  
**Target** : Cholecystokinin Receptor  
**Solubility** : DMSO: ≥ 32 mg/mL



## Biological Activity

Z-360 (Nastorazepide) is a novel potent, orally active **CCK-2/gastrin receptor** antagonist with K<sub>i</sub> of 0.47 nM. Z-360 significantly reduces gastrin-induced PKB/Akt phosphorylation in human CCK-2 receptor-expressing cells. Z-360 significantly inhibits the growth of MiaPaCa2, also suppresses pancreatic tumor growth and prolong survival in a pancreatic carcinoma xenograft model combined with gemcitabine. Z-360 prevents up-regulation of ephrin B1 gene expression and phosphorylation of NR2B via suppression of interleukin-1 β production in a cancer-induced pain model in mice.

## References

- Kawasaki D, et al. *Cancer Chemother Pharmacol*. 2008 Apr;61(5):883-92.  
 Meyer T, et al. *Eur J Cancer*. 2010 Feb;46(3):526-33.  
 Orikawa Y, et al. *Mol Pain*. 2010 Oct 28;6:72.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com